Latest Factor VII Stories
Twice-Weekly Prophylactic Regimen Resulted in 95% Reduction in Median Annualized Bleed Rate Compared to On-Demand DEERFIELD, Ill., Aug.
LEVERKUSEN, Germany, June 23, 2014 /PRNewswire/ -- Bayer HealthCare (Bayer) and Dimension Therapeutics, a company focused on developing novel adeno-associated virus (AAV) gene therapy
Transparency Market Research added a new report "Hemophilia Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its report store.
- Kogenate® FS antihemophilic factor (recombinant) approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A WHIPPANY,
Data showing improved pharmacokinetic profile to be presented at World Federation of Hemophilia Congress MELBOURNE, Australia, May 11, 2014 /PRNewswire/ -- Interim Phase II/III and
KING OF PRUSSIA, Pa., May 2, 2014 /PRNewswire/ -- CSL Behring today announced that the first patient has been enrolled
DUBLIN, April 17, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/fclw7g/global_hemophilia) has announced the addition of the "Global
LONDON, April 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
- The PROTECT VIII study met its primary efficacy and safety objectives for the treatment of patients with hemophilia A WHIPPANY, N.J., Feb.
- In the month which preceded the present; in the last month, as distinguished from the current or present month and all others.